Dr. Charles Cywin of the National Institute of Neurological Disorders and Stroke spoke about the programs available to support neuroscience translational research. View Slide Deck
Dr. Matthew Portnoy of the National Institutes of Health gave updates on the Small Business Innovation Research and Small Business Technology Transfer Programs. View Slide Deck
Dennis Ford of Life Science Nation shared tips on interacting with investors as you work on a strategic method of fundraising for your R&D. View Slide Deck
John Nobile of Tangen Biosciences talked about his company’s process in achieving their recent contract with BARDA. View Slide Deck
Dr. Joe Larsen of the Biomedical Advanced Research and Development Authority discussed current CBRN threats and BARDA’s role in developing and stockpiling countermeasures. View Slide Deck
Dr. Natalie Wisniewski, of Profusa, Inc., gave some insight about her company’s non-dilutive funding journey, starting with their initial grant from DARPA in 2011 through to today. View Slide Deck
Dr. James B. Phillips of USAMRMC, Department of Defense, shared with the audience the mission of the US Army Medical Research and Material Command and the Medical Technology Enterprise Consortium, discussing opportunities available for partnering and engaging with Industry. View Slide Deck
Ram May-Ron, Managing Partner of the FreeMind Group, opened the 13th Annual Non-Dilutive Funding Summit with a few comments on the value of non-dilutive funding to the life sciences industry.
Adam Ruben doi:10.1126/science.caredit.a1600164 Published online Dec. 21, 2016 in Science Magazine ‘Twas the night before grant deadline, 7:15. Many creatures were stirring, thanks to caffeine. The comments accepted, the references done, In hopes someone might fund my first R01. I wrote like a showman. My prose was terrific. My font was New Roman. My aims […]
In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage […]